Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
AC Immune SA is a biotechnology business based in the US. AC Immune shares (ACIU) are listed on the NASDAQ and all prices are listed in US Dollars. AC Immune employs 125 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $4.82 |
|---|---|
| 52-week range | $4.68 - $12.50 |
| 50-day moving average | $5.50 |
| 200-day moving average | $6.59 |
| Wall St. target price | $14.46 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.07 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.82 from 2022-01-14
| 1 week (2022-01-11) | -1.83% |
|---|---|
| 1 month (2021-12-17) | -3.98% |
| 3 months (2021-10-18) | -19.53% |
| 6 months (2021-07-16) | -34.78% |
| 1 year (2021-01-15) | -18.72% |
|---|---|
| 2 years (2020-01-17) | -47.61% |
| 3 years (2019-01-18) | 11.34 |
| 5 years (2017-01-18) | 12.98 |
| Revenue TTM | $944,000 |
|---|---|
| Gross profit TTM | $-44,056,000 |
| Return on assets TTM | -20.37% |
| Return on equity TTM | -34.53% |
| Profit margin | 0% |
| Book value | $2.46 |
| Market capitalisation | $355.3 million |
TTM: trailing 12 months
We're not expecting AC Immune to pay a dividend over the next 12 months.
Over the last 12 months, AC Immune's shares have ranged in value from as little as $4.68 up to $12.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AC Immune's is 0.817. This would suggest that AC Immune's shares are less volatile than average (for this exchange).
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.